Polymorphism of the CYP3A5 gene in patients with overcrossed bronchial asthma and COPD

Abstract

Pathogenetic therapy aimed at stopping inflammation in the airways is the basis of the pharmacotherapy of AD and ACO. An adequate choice of anti inflammatory (controlling, basic, maintenance) therapy ensures the controllability of the disease and improves the quality of life of patients. One of the priority modern directions is the identification of a genetic predisposition to the development of a particular pathology, including in PBAH. According to the literature, one of the genetic markers that affect the formation and development of lung disease is the CYP3A5 cytochrome 450 family gene, in particular its A6986G polymorphism, due to its direct involvement in CS metabolism.